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Introduction: Many women living with HIV around the world are in their reproductive 
years. Adherence to antiretroviral therapy (ART) and viral suppression are of particular 
importance before, during, and after pregnancy to maintain maternal health and limit 
vertical transmission. It is important to understand what factors prevent women from 
adhering to their medications. Risk factors for poor adherence in pregnant and non-
pregnant women were examined in two different contexts. 
Methods: Cohorts of HIV-infected women on ART in the United States and in South 
Africa were examined. Pregnancy experience in the last six months in the Unites States 
cohort and becoming pregnant during follow-up in the South African cohort were 
assessed among various other risk factors for poor adherence. Prevalence of poor 
adherence at baseline and endline in the South African cohort was examined; estimates 
were stratified by pregnancy and fertility intentions and compared using equality of 
proportions tests. Poisson regression models with robust variance (as an approximation of 
log binomial models) were used to estimate crude (PR) and adjusted (aPR) prevalence 
ratios and 95% confidence intervals ([,]) of risks factors for poor adherence, separately in 
each of the cohorts and also stratified by pregnancy status. 
Results: Prevalence of poor adherence declined between baseline and endline for the 
South African cohort of women. The greatest reduction was seen in those who had 
pregnancy intentions at baseline and were pregnant during follow-up (difference in 
percentages: 12.5% [8.5, 16.5]). The independent risk factors for poor adherence to ART 
among the US cohort were low CD4 count and lower level of completed education. From 
the analyses stratified by pregnancy status, risk factors that were different between those 
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who experienced a pregnancy outcome and those who did not included age, race, 
relationship status, parity, and illicit drug use. The main risk factor for the cohort of 
women from South Africa was trying to conceive (aPrR=1.54 [1.10, 0.94]). Risk factors 
that were different between those who experienced a pregnancy during follow-up and 
those who did not were level of education completed, partner HIV status, parity, ability to 
talk to a provider, and time on HAART.  
Conclusions: Risk factors for poor adherence appear to differ between pregnant and non-
pregnant women of reproductive age in the United States and South Africa. Self-reported 
poor adherence was associated with pregnancy intentions in the South African context, 
and further research should be conducted to assess this relationship and to develop 




Advisor: Keri Althoff, PhD 














I have been very fortunate to have the support and guidance of three faculty 
members in the Department of Epidemiology: Drs. Keri Althoff, Elizabeth Golub, and 
Sheree Schwartz. This work would not have been possible without their consistent help 
and high expectations. Throughout the process, they were willing to answer any question, 
no matter how small, and push me forward to address important challenges in a timely 
but rigorous manner. Thank you to all of you for working with me to make this happen. 
I would also like to acknowledge Dr. Andrea Ruff of the Department of 
International Health for serving as my thesis reader. Thank you for the work you do and 
for being so willing to take this on.   
Thank you to Bin Liu and Lorie Benning at the WIHS Data Management and 
Analysis Center (WDMAC) for your patience and help in getting me the data that I 
needed for this thesis.  
To my cohort in the Department of Epidemiology, I cannot thank you all enough 
for the days spent in the student room “silently” writing together or the nights spent 
arguing over basic epidemiologic concepts. In you, I have made friends for life.    
To my friends and family, thank you for supporting all my decisions in the pursuit 
of this degree and this thesis, and for teaching me to pursue my work with strength and 
integrity.  
Most importantly, thank you to all the women in Johannesburg and cities around 
the United States who took part in these two cohorts and spent the time to provide us with 
this valuable information.  
 
 v 
Table of contents 
Abstract ………………………………………………………………………………ii  
Acknowledgements……………………………………………………………………iv 
Table of Contents……………………………………………………………………….v 
List of Tables…………………………………………………………………………..vii 
List of Figures………………………………………………………………………….viii 
Chapter 1: Introduction...................................................................................................1 
1.1 HIV in the United States................................................................................2 
1.2 HIV in South Africa........................................................................................2 
1.3 Importance of adherence for virological suppression.................................3 
1.4 Adherence during pregnancy.........................................................................4 
1.5 Known risk factors for poor adherence during pregnancy........................5 
Chapter 2: Methods..........................................................................................................8 
2.1 Study design, setting, and population...........................................................8 
2.2 Inclusion criteria.............................................................................................9 
2.3 Outcome definition.........................................................................................10 
2.4 Description of risk factors............................................................................12 
2.5 Statistical approach.......................................................................................17 
Chapter 3: Results...........................................................................................................21 
3.1 Population characteristics............................................................................21 
3.2 Prevalence of poor adherence by pregnancy status in South Africa........22 
3.3 Risk factors for poor adherence by pregnancy status and cohort………22 



























List of Tables 
Table 1. Characteristics of HIV-infected women on antiretroviral therapy in the United 
States, stratified by whether or not experienced a pregnancy outcome by the index visit 
(n=902) 
Table 2. Characteristics of HIV-infected women on antiretroviral therapy in South 
Africa, stratified by whether or not experienced a pregnancy during duration of follow-up 
(n=730) 
 
Table 3.  Crude and adjusted prevalence ratios for risk factors of self-reported poor 
adherence among a cohort of women from the United States (n=902) 
 
Table 4.  Crude and adjusted prevalence ratios for risk factors of self-reported poor 
adherence among South African women (n=730) 
 
Table 5. Sensitivity Analysis: Crude and adjusted prevalence ratios for risk factors of 
poor adherence defined as having a viral load below the detectable limit among South 
African women (n=730) 
 
Table 6.  Sensitivity Analysis: Crude and adjusted prevalence ratios for risk factors of 





List of Figures 
Figure 1. Conceptual framework of risk factors for poor adherence in the cohort of 
women from the United States 
Figure 2. Conceptual framework of risk factors for poor adherence in the cohort of 
women from South Africa 
Figure 3. Definition of study visits and timing of assessment of predictors and adherence 
Figure 4. Comparison of study design and cohort characteristics for two urban cohorts of 
women from the United States and South Africa 
Figure 5. Definition of poor adherence by cohort and level of analysis: self-reported 
adherence and viral load as a proxy for adherence 
Figure 6. Prevalence of detectable viral load, comparing HIV-infected women on 
antiretroviral therapy by whether or not they experienced a pregnancy and pregnancy 
intentions in South Africa, 2009-2011 (n=730) 
Figure 7. Forest plot of patient demographics as predictors of poor adherence among 
HIV-infected women on antiretroviral therapy in the United States, overall (n=902) 
Figure 8. Forest plot of reproductive-health characteristics as predictors of poor 
adherence among HIV-infected women on antiretroviral therapy in the United States, 
overall (n=902) 
 ix 
Figure 9. Forest plot of medication-related characteristics as predictors of poor adherence 
among HIV-infected women on antiretroviral therapy in the United States, overall 
(n=902) 
Figure 10. Forest plot of patient demographics as predictors of poor adherence among 
HIV-infected women on antiretroviral therapy in the United States stratified by whether 
or not they experienced a pregnancy outcome by the index visit (n=902) 
Figure 11. Forest plot of reproductive-health characteristics as predictors of poor 
adherence among HIV-infected women on antiretroviral therapy in the United States 
stratified by whether or not they experienced a pregnancy outcome by the index visit, 
(n=902) 
Figure 12. Forest plot of medication-related characteristics as predictors of poor 
adherence among HIV-infected women on antiretroviral therapy in the United States 
stratified by whether or not they experienced a pregnancy outcome by the index visit 
(n=902) 
Figure 13. Forest plot of patient demographics as predictors of poor adherence among 
HIV-infected women on antiretroviral therapy in South Africa, overall (n=730) 
Figure 14. Forest plot of reproductive-health characteristics as predictors of poor 
adherence among HIV-infected women on antiretroviral therapy in South Africa, overall 
(n=730) 
 x 
Figure 15. Forest plot of medication-related characteristics as predictors of poor 
adherence among HIV-infected women on antiretroviral therapy in South Africa, overall 
(n=730) 
Figure 16. Forest plot of patient demographics as predictors of poor adherence among 
HIV-infected women on antiretroviral therapy in South Africa stratified by whether or 
not they experienced a pregnancy during follow-up (n=730) 
Figure 17. Forest plot of reproductive-health characteristics as predictors of poor 
adherence among HIV-infected women on antiretroviral therapy in South Africa stratified 
by whether or not they experienced a pregnancy during follow-up (n=730) 
Figure 18. Forest plot of medication-related characteristics as predictors of poor 
adherence among HIV-infected women on antiretroviral therapy in South Africa stratified 








Chapter 1: Introduction 
Close to 37 million people are living with HIV around the world [1]. Despite 
increasing access to and availability of treatment and a real decline in new infections, 
close to a 40% decline since 2000, there are still two million new infections every year 
[1]. Globally, young women, ages 15-24 years, are at particularly high risk, facing almost 
double the risk of HIV infection as young men of the same age [2]. About half of all 
individuals living with HIV are women, and AIDS-related deaths continue to be the 
leading cause of death among women of reproductive age [1].  
 The majority of women living with HIV around the world are in their reproductive 
years, highlighting the critical need to better understand the issues of pregnancy and 
motherhood as they relate to HIV. Adherence to antiretroviral therapy (ART) is important 
for all HIV-infected individuals in order to maximize clinical benefit and reduce HIV 
transmission [3]. Adherence and viral suppression are of particular importance before, 
during, and after pregnancy in order to maintain maternal health and limit vertical 
transmission (from mother to baby) [4]. While progress has been made to achieve more 
frequent testing, earlier diagnoses, and better linkage to care, many individuals are not 
retained in care and fail to adhere [3]. It is important to understand how pregnancy and 
other risk factors are associated with women failing to adhere to their medications.  
 Pregnant women have been previously shown to be at particular risk of having poor 
adherence [5]. Very little is known on specific risk factors for poor adherence among 
pregnant and similar non-pregnant women of reproductive age [5]. As very little 
information is available on risk factors for poor adherence in this population, a risk factor 
analysis will serve as an important descriptive tool for identifying important associations 
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for further exploration, and to begin to identify targets for intervention [6]. In this 
analysis, risk factors for self-reported poor adherence in pregnant and non-pregnant 
women will be examined in two different contexts: a cohort of women in the United States 
and a cohort of women in South Africa, as it is of interest to qualitatively examine 
differences in barriers to ART adherence in low and high-income settings.  
 
1.1 HIV in the United States 
 
In the United States, a resource-rich nation with over 300 million individuals, 
HIV affects less than 0.1% of the population. There are 1.2 million people living with 
HIV (PLHIV), with about 50,000 new infections each year [7]. About 25% of PLHIV in 
the United States are women [7]. Black heterosexual women remain the worst affected, 
accounting for almost 75% of new infections in women [7]. While more than half of 
women in the United States have reported being tested at least once for HIV in their lives, 
only 20% have been tested in the past year [8]. Among those women living with HIV, 
20% remain undiagnosed, and just over 30% are virally suppressed [8].  
 
1.2 HIV in South Africa 
 
South Africa has one of the highest national HIV prevalence estimates in the 
world. Close to 20% of all adults, or 7 million individuals, ages 15-49 are living with 
HIV [9]. Women of reproductive age bear a disproportionate burden of disease, making 
up more than half of all HIV cases [9]. With increased national attention and the 
implementation of The National Strategic Plan 2007-2011, 1 in 4 individuals had been 
tested in the last year as of 2010 [10]. Increased efforts for the prevention of mother to 
child transmission (PMTCT) resulted in more testing among women of reproductive age 
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[10]. While there have been improvements in ART access, only about 42% of those 
eligible for treatment are on treatment, and fewer are virally suppressed [11]. Even with 
reductions in maternal to child transmission and increased access of PMTCT services, 
there has been no change in maternal mortality [11].   
Despite these persistent numbers, real improvements in life expectancy and 
quality of life have been made in the last decade [11]. Because of these advances and the 
dramatically altered natural history of HIV infections in both high and low income 
countries, many women living with HIV and their partners are living normal lives, and 
are either already parents or hope to expand their families in the future [12]. It has been 
consistently shown that people living with HIV (PLHIV) have comparable pregnancy 
intentions to individuals not affected by HIV [12].   
1.3 Importance of virological suppression during pregnancy 
 
ART reduces the virus’ ability to replicate and infect new cells, resulting in 
virologic suppression, defined as having a plasma HIV viral load below the assay limit of 
detection [1]. It is important to understand the level of adherence to ART that is required 
for virological suppression.  
In an early study using older protease inhibitor (PIs) combination regimens, it was 
found that adherence ≥95% of the time was required not only for virological suppression, 
but also for other improvements in health, including increased CD4 count and reduced 
number of HIV-related infections, hospitalizations, and deaths [13]. More recent studies 
with efavirenz and other non-nucleoside reverse transcriptase inhibitor (NNRTIs) based 
regimens suggest that adherence ≥80% of the time would be sufficient for achieving viral 
suppression and immune recovery [14]. It has been shown that different regimens may 
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allow for different types of non-adherence, with boosted PI-based regimens 
accommodating intermittent adherence and NNRTI-based regimens accommodating 
scheduled, longer breaks in treatment [15, 16]. It should be noted, however, that 
suppression is associated with adherence in a linear dose-response relationship, and 
therefore it is often recommended that maximum adherence to ART be promoted at all 
times, especially for pregnant women [5]. Additionally, lower levels of adherence and 
intermittent use can be associated with drug resistance [15].    
Without virologic suppression, pregnancy with HIV can threaten the health of the 
mother and the child [17]. Some risk of horizontal and vertical transmission will persist 
in the absence of a cure, but antiretroviral therapy (ART) for the mother and subsequent 
virological suppression can dramatically reduce these risks [17]. Optimal adherence to 
ART is critical to the management of HIV infection, and the promotion of the health of 
the mother, her partner, and her child [3-5]. 
 
1.4 Adherence during pregnancy 
Nachega et al., 2012 conducted a systematic review of 51 studies, including 14 
from the United States and five from South Africa, to estimate ART adherence during 
pregnancy and just after pregnancy in settings around the world [5]. The included studies 
utilized different measures for capturing adherence to ART (e.g. pill count, self-report, 
and blood drug concentration), and had varying thresholds for defining “good 
adherence,” (e.g. greater than 80%, greater than 90%, etc.) [5]. A pooled estimate of the 
proportion of women who were adherent during pregnancy suggested that about 74% 
(95% CI: [69.3, 77.5]) achieved adherence greater than 80% of the time [5]. The findings 
 5 
of the study also suggest that reaching adequate adherence levels proves especially 
challenging during the postpartum period, with only about 53% (95% CI: [32.8, 72.7]) 
achieving good adherence [5]. In low and middle income countries, like South Africa, 
women fared better overall with adherence levels at 76% (95% CI: [72.2, 79.7]) as 
compared with women in high-income settings, where a pooled estimate of 62% (95% 
CI: [50.1, 73.3]) was observed, but this difference became non-significant with the 
exclusion of studies examining single-dose nevirapine only regimes [5].  
One prospective study conducted in the United States among 500 pregnant 
women reported 75% of participants not missing any doses on the four days before their 
study visit; this proportion dropped significantly at 6, 24, and 48 weeks postpartum, to as 
low as 64% [18]. The women with optimal adherence in this cohort had significantly 
lower viral loads than those with suboptimal adherence [18]. A study conducted in 
KwaZulu-Natal, South Africa, examined counseling and clinical notes of 100 Zulu 
women and found good adherence (defined as >95% adherent) in 61% of women during 
pregnancy [19].  
Despite having disparate measures of adherence and differing thresholds for 
“good” adherence, these studies suggest that many women are sub-optimally adherent 
during and just after pregnancy, and that there is a need for strategies to improve 
adherence in both low and high-income settings.  
 
1.5 Known risk factors for poor adherence during pregnancy 
Little information is available on risk factors for poor adherence to ART among 
pregnant women and other women of reproductive age. An early study conducted in 1997 
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in the general population reviewed the available literature and broadly outlined younger 
age, unstable housing, low income and lack of insurance, lack of transportation and child 
care, mental illness, poor social support, poor knowledge of medications, and illicit drug 
use as being some potential risk factors that could affect adherence to HIV therapy [20]. 
Some commonly identified risk factors in resource-rich settings, but not necessarily 
unique to pregnant women, also include fear of disclosure of HIV status, complex 
regimens, diminished sense of self-worth, and not accepting their HIV seropositivity [21].  
In resource-poor settings, more work has been done to investigate both the 
barriers to and facilitators of adherence to ART among pregnant women, especially for 
the purposes of PMTCT treatment adherence. Poor knowledge of HIV and vertical 
transmission, therapy misconceptions, and psychological issues following HIV diagnosis 
as additional barriers were all identified as individual-level barriers [22]. Other barriers 
identified include domestic violence, preference for traditional healers and birth 
attendants, stigma associated with HIV and parenthood, and issues with disclosure to 
family [22]. In addition, Gourlay et al., 2013, along with others, have identified some 
serious health-systems level barriers, including stock-outs of pills, staff shortages, and 
perceived negative health workers attitudes [22, 23]. There is little to no literature 
comparing risk factors for poor adherence in pregnant women and other women of 
reproductive age. 
The aims of this thesis were: 
1. to examine prevalence of poor adherence in South African women,  
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2. to identify risk factors for poor adherence and investigate differences in 
risk factors by pregnancy status in both South Africa and the United 
States.  
First, levels of ART adherence were compared between women who became pregnant 
and those who did not among a cohort of HIV-infected women in South Africa. Second, 
risk factors for poor adherence were examined and the effects stratified by whether or not 
a woman experienced a pregnancy during follow up among the same cohort of HIV-
infected women in South Africa. Finally, risk factors for poor adherence were examined 
and the effects stratified by whether or not a woman experienced a pregnancy outcome as 
compared with not experiencing a pregnancy outcome among a cohort of HIV-infected 














Chapter 2: Methods 
 
2.1 Study design, setting, and populations 
The present study was nested in two existing urban cohorts of HIV-infected 
women on ART: one cohort in the United States and one in South Africa.  
The cohort of women studied from the United States was a sample of the 
Women’s Interagency HIV Study (WIHS) and came from six sites: Bronx, New York, 
Brooklyn, New York, Washington DC, Los Angeles, California, San Francisco, 
California, and Chicago, Illinois. The WIHS is the largest prospective cohort study of 
HIV among US women, and includes a structured interview, a clinical examination, and 
laboratory testing at semi-annual study visits. Details of the WIHS have been published 
previously [24]. Prior to the analyses presented here, a descriptive study of ART use 
before, during, and after pregnancy was conducted in the WIHS [25]. This parent study 
propensity-score matched WHIS participants by whether or not they had reported a 
pregnancy outcome, defined as a live birth, a termination, a miscarriage, etc., anytime in 
the six months prior to that visit [25]. Risk factors for poor adherence were measured at 
the visit prior to the study’s baseline (index) visit, or six months before the index visit, 
and adherence was measured at the index+1 visit, or six months after the index visit 
(Figure 1). The analyses presented here were nested in this previous WIHS study. 
The cohort of women studied from South Africa was part of a clinical cohort 
based out of four publicly-funded ART health centers: Hillbrow Community Health 
Centre, South Rand Hospital, Urban Health Clinic, and Rosettenville Primary Health 
Centre, in Johannesburg, Gauteng between 2009 and 2011. Recruitment was conducted 
by study staff in clinic waiting rooms. Information was collected at one to three month 
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clinic visits, and participants were followed for about one year or until the end of 
pregnancy. Participants were asked questions regarding demographics, reproductive 
history, fertility intentions, and patient provider relations during a baseline interview. 
Interviews were conducted in English, Zulu, and Sotho. Pregnancy testing, contraceptive 
use, and fertility intentions were assessed by study staff at each visit, and patient files 
were used to obtain additional clinical information. For the cohort of women from South 
Africa, risk factors for poor adherence were measured at the baseline visit and self-
reported adherence was measured at endline (Figure 1). 
 
2.2. Inclusion criteria 
For both cohorts, women were included in this study if they were living with HIV, 
on antiretroviral therapy, and at risk of pregnancy.  
Women from the United States were sampled from the parent study describing 
ART use before, during, and after pregnancy. In the present study, women age ≤52 years 
with at least one male sex partner were included if they had not previously experienced a 
hysterectomy, oophorectomy, or tubal ligation. Women who were not on treatment in the 
six months leading up to the index+1 visit were excluded because they could not have 
had self-reported adherence data at the index+1 visit (Figure 1).   
Women from the South African cohort were sampled. Women 18-35 years old, 
who had been sexually active in the last 12 months, had a negative urine-based pregnancy 
test at baseline, and were not breastfeeding, had not experienced a tubal ligation, 
sterilization, or prior infertility diagnosis were eligible for inclusion. Based on the 
structure of the interviews and the study design, self-reported adherence was only 
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collected at endline and therefore, only those women with endline data were included in 
this study.   
 
2.3 Outcome definition 
The main outcome of interest was self-reported poor adherence. Self-reported 
adherence was chosen as the primary outcome of interest rather than viral load 
suppression, a biologic measure of adherence, because it is possible that for some 
individuals, suppressed viral load may not be a true indicator of good adherence. Elite 
controllers in the absence of treatment, as an example, often have viral loads similar to 
that of those who are adherent to medications [26]. In the absence of other adherence 
measures, e.g. pill count, pharmacy claims data, etc., self-reported adherence was chosen 
as the primary outcome. In the United States, women were characterized as having poor 
adherence if they reported being adherent to antiretroviral medication <95% of the time 
over the last six months. In the cohort of women from South Africa, women were 
characterized as having poor adherence if they were adherent to antiretroviral medication 
<95% of the time, which was captured if they reported missing pills on one or more days 
in the last two weeks.   
Among the WIHS women, level of adherence was assessed six to twelve months 
following the end of a pregnancy or six months after a comparable visit in those who did 
not report a pregnancy outcome. Among the South African women, level of adherence 
was assessed at the end of pregnancy or just after the end of pregnancy or at a 
comparable visit in those who did not experience a pregnancy during follow-up.  
 11 
Figure 1. Definition of study visits and timing of assessment of predictors and adherence   
 12 
 
2.4 Description of risk factors  
Pregnancy was the primary risk factor of interest, defined as pregnancy during 
follow-up in the South African women, and pregnancy outcome reported at the index 
visit in the American women. Additional risk factors for poor adherence were considered 
based on a priori knowledge and hypothesized relationships based on a review of the 
literature. Risk factors for poor adherence from three categories were examined: patient 
characteristics, reproductive-health related characteristics, and other healthcare-related 
characteristics. Two separate conceptual frameworks can be found relating the risk 
factors to poor adherence for each of the two cohorts (Figures 2 & 3).  
 In the United States, age, income level, education, and race were patient risk 
factors. Relationship status, pregnancy intentions, and parity were reproductive-health 
related risk factors. CD4 count, health insurance, depressive symptoms, and illicit drug 
use were healthcare-related risk factors. Exploratory data analysis and a review of the 
literature informed the way we modeled the risk factors, to allow for appropriate 
inference and comparison of our findings with other studies. Age (in years) was 
categorized into three groups: 18-24, 25-33, and ≥34 years. Yearly household income 
level was dichotomized with reference to the 2008 annual poverty threshold for a family 
of four ($24,000) and within the confines of WIHS data collection (household income 
was categorized as follows: $6000 or less, $6001-$12000, $12001-$18000...$75,000 or 
more) [27]. Education completed was categorized into three groups: less than high 
school, high school graduate, or more than high school. Race was classified as Black and 
non-Black. Relationship status was dichotomized, with women who were either married 
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or living with a partner categorized as being in a relationship. Whether or not women 
were currently trying to conceive was dichotomized. Parity was categorized into three 
groups: no children, one child, or two or more children. CD4 count was categorized into 
four groups: 0-200, 201-350, 351-500, or ≥500 cells/μL. Illicit drug use, depressive 
symptoms, and whether or not women had insurance were all dichotomized (yes/no). 
Though originally considered for inclusion, any contraceptive use was not included as a 
risk factor as it was collinear with intention to conceive.  
In the South African setting, age, income level, and education were patient-level 
risk factors. Current partner HIV status, pregnancy intentions, and parity were 
reproductive-health related risk factors. CD4 count, time on highly active antiretroviral 
therapy (HAART), and ability to talk to primary healthcare provider other healthcare-
related risk factors. Age (in years) was categorized into three groups: 18-24, 25-33, and 
≥34 years. Monthly household income level was dichotomized to above and below the 
poverty line, or about $120 USD per month, which was based on the 2009 poverty 
threshold for a family of four. The conversion rate from Rand (ZAR) to Dollars (USD) 
was used from 2009 [28, 29]. Education completed was categorized into three groups: 
primary or less, some secondary, or secondary or more. Information on the woman’s 
current partner’s HIV status was dichotomized into HIV negative (i.e. a serodiscordant 
partner) and other. The rationale behind this was that those women with a serodiscordant 
partner have the most to gain from remaining adherent to their medication. Whether or 
not women were currently trying to conceive was dichotomized (yes/no). Parity was 
categorized into three groups: no children, one or two children, or more than two 
children. CD4 count was categorized into four groups: 0-200, 201-350, 351-500, or ≥500 
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cells/μL. While it was considered that time on HAART might be collinear with age, in 
univariate analyses it was shown to have a different effect on poor adherence than age. 
Time on HAART was therefore included and categorized into three groups: less than 1 
year, between 1 and 4 years, and more than 4 years. Whether or not a woman felt that she 
could talk to her main health care provider was dichotomized (yes/no). Like in the WIHS 
context, contraceptive use was not included.  
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2.5 Statistical approach 
While parsimony was not necessarily a primary goal of this risk factor analysis, 
factors were included after assessment of univariate associations and collinear 
relationships. 
Data were analyzed using Stata/IC 13.1 for Mac (StataCorp LP, College Stata, 
TX). A p-value of 0.05 was used as a cutoff for statistical significance.  
 
Missing data  
 
Missing data in both cohorts was low. There was less than 2.5% missingness in 
income (2.4%), relationship status (1.9%), race (1.2%) and insurance (1.2%) for the 
cohort of women from the United States. There was missingness in only one risk factor, 
income (2.5%), for the South African cohort. Complete case analysis was used as 
missingness was thought to be sufficiently low.  
Selection bias 
Selection bias for both cohorts was examined by comparing characteristics of 
those in the study prior to application of our inclusion/exclusion criteria (source 
population), and those included in these analyses (study population, see Appendix). This 
comparison allowed us to examine the representativeness of the women in our study 




A merging of the two datasets was originally considered to assess the importance 
of cohort, or context, on poor adherence in pregnant and non-pregnant women of 
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reproductive age, but it was determined that because of the disparate nature of the study 
questions and study design, the analyses must be stratified by geographical context, thus 
eliminating the possibility of examining geographical context as a risk factor.  
Pearson’s chi-square tests for independence were used to explore the associations 
between various index-1 visit characteristics (age, income, education, race, relationship 
status, pregnancy intentions, parity, CD4 count, insurance, illicit drug use) and whether 
or not a woman reported a experiencing a pregnancy outcome at the index visit for the 
cohort of women from the United States and separately for various baseline 
characteristics (age, income, education, relationship status, pregnancy intentions, parity, 
CD4 count, time on HAART, ability to talk to provider) and whether or not a woman 
experienced a pregnancy during follow-up in the South African cohort. For further detail, 
age and parity were also examined as continuous variables, and statistical associations 
were assessed using Wilcoxon-rank sums test for equality of medians.  
For Aim 1, the prevalence of women who had poor adherence in the South 
African cohort was assessed at baseline, or prior to pregnancy, and at endline, during or 
just after pregnancy or a comparable time for those women who did not become pregnant 
during follow-up. Because self-reported adherence was not available at the baseline visit, 
a viral load above the detectable limit (greater than or equal to 50 copies per milliliter) 
was used as a proxy for poor adherence. The prevalence of poor adherence at baseline 
was compared with that at endline, and stratified by whether or not the participant 
experienced a pregnancy during follow-up and by their pregnancy intentions at the start 
of the study. HIV viral loads used to estimate prevalence of poor adherence were 
measured at the baseline and closest to the endline interview. Standard errors and 
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confidence intervals were calculated for the proportions using Clopper-Pearson intervals 
for binomial proportions. Proportions were compared using tests on the equality of 
proportions. The prevalence of adherence in the WIHS was not examined because these 
HIV viral load measurements were not available in our study population [25]. 
 
For Aim 2, Poisson regression models with robust variance estimation were used 
to approximate log binomial models, because the prevalence of the outcome exceeded 
10% and prevalence ratios were the most appropriate estimate given the study design. 
Log binomial models were attempted, but they failed to converge. Crude (PR) and 
adjusted (aPR) prevalence ratios estimated the association of the risk factors with poor 
adherence.  
Due to the difference in the context, models were stratified by cohort (WIHS 
women in the US and the South African cohort). Selection of risk factors for the final 
adjusted model were chosen based on univariate associations and a priori knowledge. 
Our a priori belief was that risk factors for poor adherence would be different among 
pregnant and non-pregnant women. We conducted a stratified analysis, building separate 




A sensitivity analysis was conducted in the South African cohort of women using 
detectable viral load as the outcome instead of self-reported poor adherence to assess if 
risk factors changed based on a biologic vs. self-reported outcome. Another sensitivity 
analysis was conducted in the South African cohort of women in which the cut-off for 
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self-reported poor adherence was changed from <95% to <85% adherence to assess how 























Chapter 3: Results 
3.1 Population characteristics 
United States 
A total of 902 WIHS HIV-infected women in the United States were included in 
this study. From the 1305 women in the source population, 403 were excluded because 
they did not have adherence data at the index+1 visit. Among the 902 women included, 
median age was 33 years (IQR: 27.8-37.8). More than half (54%) of women completed 
high school or more; 37% completed some high school and 9% completed less than high 
school. About 3 in 4 women were living below the poverty line (76%). Less than 20% of 
women reported any illicit drug use, and 41% had depression symptoms as assessed by a 
CESD-score. A majority of women included in this study identified as Black (66%). 
There was a relatively even distribution for all characteristics measured at the index-1 
visit between those women that had reported a pregnancy outcome at the index visit and 
those that had not, with no statistically significant difference between groups (Table 1). 
South Africa 
From the original 850 women who were enrolled at baseline in the South African 
cohort, 730 (86%) women had endline data and were included in this analysis. The 
median age was 30.5 years old (IQR: 27.5-33.1). Over 90% of women were living below 
the poverty line, and close to 9% had completed primary school or less. About 93% of 
women were in a self-reported relationship at baseline, and 12% of them were currently 
trying to conceive. Most women had been on HAART for less than four years, with only 
7% of women on treatment for more than four years. There was no statistically 
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significant association between any of the baseline characteristics and whether or not the 
women experienced a pregnancy during follow-up (Table 2).  
 
3.2 AIM 1: Prevalence of poor adherence by pregnancy status in South Africa 
Prevalence of poor adherence was measured by detectable viral load during the 
period of baseline to endline in the South African cohort of women. All women at 
baseline were at risk of pregnancy and not pregnant yet. Overall, poor adherence as 
indicated by viral load above the detectable limit at baseline was 25% (95% CI: [22, 28]). 
Prevalence of poor adherence was significantly lower at endline, 17% (95% CI: [14, 20]). 
When examining prevalence of poor adherence at either baseline or endline stratified by 
whether or not a woman experienced a pregnancy during follow-up and whether or not 
she had pregnancy intentions at baseline, there did not appear to be any statistically 
significant difference between groups (Figure 6). All four groups experienced a decline in 
prevalence of poor adherence between baseline and endline (Figure 6).  While the 
difference in prevalence estimates of poor adherence between baseline and endline are 
very similar for pregnant (difference in percentages: 7% [3, 11]) and non-pregnant 
women (difference in percentages: 8% [4, 12]), the steepest decline in poor adherence 
was seen in those women who were pregnant and trying to become pregnant at baseline 
(difference in percentages: 13% [9, 17]).  
3.3 AIM 2: Risk factors for poor adherence by pregnancy status and cohort 
United States 
In the United States cohort of women, there was no association between having 
reported a pregnancy outcome and prevalence of self-reported poor adherence in either 
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univariate (PR=1.00 [0.78, 1.28]) or multivariate analyses (aPR=1.00 [0.78, 1.29]), after 
adjusting for other risk factors (Table 3). 
 For patient demographics as risk factors, those who completed more than high 
school had a significantly lower prevalence of poor adherence than those who completed 
less than high school (aPR=0.66 [0.47, 0.94]). Age did not appear to be associated with 
poor adherence. Both black race as compared with other race (aPR=1.12 [0.86, 1.46]) and 
those with a yearly household income above the poverty line compared with below the 
poverty line were associated with a higher prevalence of poor adherence, though not 
statistically significant (Figure 7). When examining stratified estimates, age did appear to 
be associated with poor adherence, though not significantly. In those women who 
experienced a pregnancy outcome at the index visit, older age was associated with a 
higher prevalence of poor adherence, and in those women who did not, older age was 
associated with a lower prevalence of poor adherence. In those women who experienced 
a pregnancy outcome, black race was associated with a lower prevalence of adherence, 
and in those women who did not, black race was associated with a higher prevalence of 
poor adherence when compared with other races (Figure 10).  
For reproductive-health characteristics as risk factors, no factor remained 
statistically significantly associated with the outcome in multivariate analyses. Though 
not significant, those who were currently trying to conceive at the index-1 visit had a 
higher prevalence of poor adherence than those who were not trying (aPR=1.21 [0.73, 
2.00]). Those who were in a relationship had a lower prevalence of poor adherence than 
those who reported being not in a relationship (aPR=0.88 [0.68, 1.13]). Those who 
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reported having two or more children had a higher prevalence of poor adherence as 
compared with those with no children (PR=1.17 [0.76, 1.65]) (Figure 8). In those women 
who experienced a pregnancy outcome, the association between being in a relationship 
and poor adherence disappears, whereas for those who did not experience a pregnancy 
outcome, being in a relationship remains protective when compared with being single. 
Having one living child as compared with having none is associated with higher 
prevalence of poor adherence in those who experienced a pregnancy outcome, and with 
lower prevalence of poor adherence in those who did not experience a pregnancy 
outcome (Figure 11).   
For medication-related and other characteristics as risk factors, those with CD4 
counts >200, at all levels, had a significantly lower prevalence of poor adherence as 
compared with those with CD4 counts ≤200. Those who reported using illicit drugs had a 
higher prevalence of poor adherence as compared with those who did not (aPR=1.21 
[0.91, 1.60]), though not statistically significant. Other non-significant relationships 
include those with depressive symptoms having a lower prevalence of the outcome 
compared with those without (aPR=0.86, [0.67, 1.10]) and those who had insurance 
having a higher prevalence of the outcome compared with those without (aPR=1.32 
[0.77, 2.27]) (Figure 9). In those women who experienced a pregnancy outcome, using 
illicit drugs as compared with those not using was associated with lower prevalence of 
poor adherence, whereas in those women who did not experience a pregnancy outcome 
illicit drug use was associated with a higher prevalence of poor adherence (Figure 12).  
South Africa 
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In the South African cohort of women, there was a non-significant association 
between having a pregnancy during follow-up and prevalence of poor adherence, with 
women who became pregnant during follow-up having a lower prevalence of poor 
adherence than those who did not become pregnant (aPR=0.85 [0.61, 1.19]) in univariate 
analysis and in multivariate analysis (aPR=0.81 [0.58, 1.12]), after adjusting for other 
risk factors (Table 4).  
For patient demographics as risk factors, no factor remained statistically 
significantly associated with the outcome in multivariate analyses. Older age was 
associated with lower prevalence of poor adherence, with those who were between 25 
and 33 years (aPR=0.88 [0.53, 1.46]) and those who were 34 or older (aPR=0.68 [0.41, 
1.13]) when compared with those who were younger than 25 years. Education did not 
appear to be associated with poor adherence. Those with a monthly household income 
above the poverty line as compared with those below the poverty line had a higher 
prevalence of poor adherence (aPrR=1.15 [0.76, 1.75]), though not statistically 
significant (Figure 13). When examining stratified estimates, education did appear to be 
associated with poor adherence, though not significantly. In those women who 
experienced a pregnancy during follow-up, some secondary school was associated with a 
lower prevalence of poor adherence, while secondary school or more was associated with 
a higher prevalence of poor adherence compared with primary school or less. In those 
women who did not experience a pregnancy during follow-up, the effects of education 
were just the opposite, with some secondary being associated with a higher prevalence of 
poor adherence and secondary or more being associated with a lower prevalence of poor 
adherence compared with primary school or less (Figure 16). 
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For reproductive-health characteristics as risk factors, positive pregnancy 
intentions were significantly associated with poor adherence, with those who were trying 
to conceive having a higher prevalence of poor adherence than those who were not trying 
to conceive (aPR=1.54 [1.10, 0.94]). Relationship status did not appear to be associated 
with the outcome. While not significant, having one child as compared with having no 
children was associated with a lower prevalence of poor adherence (aPR=0.87 [0.62, 
1.23]) (Figure 14). When stratifying by whether or not a woman experienced a pregnancy 
during follow-up or not, partner HIV status did appear to be associated with the outcome, 
though not statistically significantly. In women who became pregnant during follow-up, 
having a current partner that was HIV negative was associated with high prevalence of 
poor adherence, while among those who did not become pregnant, having a current 
partner that was HIV negative was associated with a lower prevalence of poor adherence. 
(Figure 17)  
For medication-related and other characteristics as risk factors, no factor remained 
statistically significantly associated with the outcome in multivariate analyses. CD4 count 
> 200 and ability to talk to a health care provider did not appear to be associated with the 
outcome. More than four years on HAART as compared with less than a year was 
associated with a higher prevalence of poor adherence (aPR=1.45 [0.85, 2.46]) (Figure 
15). When stratified by whether or not a woman became pregnant during follow-up, 
having the ability to talk to a provider was associated with lower prevalence of poor 
adherence among pregnant women, but there was no association among non-pregnant 
women.  For those who became pregnant, being on HAART for more than four years was 
associated with a lower prevalence of poor adherence compared with those who were on 
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HAART for less than one year, while it was associated with a higher prevalence of poor 
adherence among those who did not become pregnant (Figure 18).  
Sensitivity Analyses 
When examining risk factors for poor adherence among the South African cohort 
of women and using detectable HIV viral load as measurement of poor adherence, trying 
to conceive was no longer observed as an independent risk factor. Having completed 
secondary school or more was significantly associated with a lower prevalence of poor 
adherence compared with having completed primary or less  (aPR=0.59 [0.36, 0.97]). 
Higher CD4 count, > 200, was also significantly associated with a lower prevalence of 
poor adherence (Table 5). 
In the sensitivity analysis examining risk factors for poor adherence among the 
South African cohort of women using a less stringent cutoff for poor adherence, a cutoff 
of ≥85% instead of ≥95%, those who were 34 years or older had significantly lower 
prevalence of poor adherence compared with those 18-24 years (aPR=0.40 [0.17, 0.96]) 












Chapter 4: Discussion 
4.1 Discussion 
Overall, prevalence of poor adherence, as measured by detectable viral load, 
declined over the course of the study for all women in the South African cohort, and the 
greatest decline was seen in those who were pregnant and trying to get pregnant at the 
beginning of the study. Risk factors for self-reported poor adherence differed between the 
two cohorts. The independent risk factors for poor adherence to ART for the cohort of 
women from the United States were low CD4 count and lower level of completed 
education. Risk factors that were different between those who experienced a pregnancy 
outcome and those who did not were age, race, relationship status, parity, and illicit drug 
use. The main risk factor for the cohort of women from South Africa was trying to 
conceive. Risk factors that were different between those who experienced a pregnancy 
during follow-up and those who did not were level of education completed, partner HIV 
status, parity, ability to talk to a provider, and time on HAART.  
Prevalence of poor adherence by pregnancy status in South Africa 
The prevalence of poor adherence was not significantly different in those who 
experienced a pregnancy during follow-up compared with those who did not experience a 
pregnancy, at both baseline, before any of the women had become pregnant, and at 
endline, at the end of pregnancy or after pregnancy (Figure 6). While there are very few 
data available comparing the adherence levels of pregnant women to that of their non-
pregnant counterparts, this finding differs from the available literature, which suggests 
that pregnant women have higher levels of adherence. One study conducted on a group of 
165 women living with HIV and attending a multidisciplinary clinic in Puerto Rico found 
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that when asked about adherence to ART in a three-day adherence questionnaire, 
pregnant women (n=37) reported higher levels of adherence than non-pregnant women, 
and that the difference was significant [30]. In a prospective cohort study of 72 pregnant 
and 79 non-pregnant women, it was shown that a greater proportion of pregnant women 
met the criteria for 95% adherence, by both pill count and self-report, than non-pregnant 
women [31]. That being said, these are the results from two small studies in two very 
different contexts from South Africa: Puerto Rico and Brazil. Part of the difference 
between the results of these studies and our findings may have to do with differences in 
populations, differences in when and how women were asked about adherence, or even 
differences in perceived social desirability of response. For example, it is possible that 
pregnant women in these studies were differentially more likely to report being more 
adherent than their non-pregnant counterparts as compared with the women in our South 
African cohort, or that pregnant women in the South African cohort were differentially 
less likely to report being adherent [32]. It is also possible that there is a true difference in 
levels of adherence in these other contexts, but not in South Africa, and this could be due 
to a number of things including poor knowledge of PMTCT, poor uptake and access of 
treatment, etc.  
There are almost no data available on the difference in adherence levels between 
women with intended pregnancies and unintended pregnancies, but it was shown here 
that if the pregnancy is desired, there exists the steepest decline in poor adherence. This 
could suggest the need for more research into how the promotion of planned pregnancies 
and family planning over unintended pregnancies can improve adherence.    
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Independent risk factors: WIHS 
It was found that those who completed more than high school had a lower 
prevalence of poor adherence compared with those who had less than a high school 
education. This association remained significant when examining those who experienced 
a pregnancy outcome only, but did not hold when restricted to those who did not report a 
pregnancy outcome at the index visit. Other studies examining risk factors for poor 
adherence among women did not find any association with education, but did find that 
those with better understanding of the dosing and complexity of their regimens were 
more likely to be adherent [33].   
Reduced CD4 count was significantly associated with increased prevalence of 
poor adherence. When examining stratified estimates, this association remained 
significant when examining those who did not experience a pregnancy outcome only. 
Higher CD4 count and lack of clinical AIDS has been previously shown to be associated 
with reduced likelihood of skipping doses of treatment [18, 33].  
Although this descriptive analysis begins to explore factors influencing ART 
adherence during pregnancy, further research is needed to isolate these associations in a 
longitudinal study design in order to determine if they are causally related to poor 
adherence in pregnant and non-pregnant women in the US.  
Independent risk factors: South Africa 
In the South African cohort of women, trying to conceive was significantly 
associated with higher prevalence of self-reported poor adherence, and remained 
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significant in stratified analyses for those who did not become pregnant during the study. 
This is a very interesting finding, as it potentially suggests four things. First, women who 
are trying to get pregnant are feeling healthy enough to try conceiving a child, and 
therefore feel less urgency to adhere to ART. Second, women who are trying to get 
pregnant are prioritizing trying to conceive and other things in their life over ART 
adherence. Third, women who are trying to get pregnant underreport ART adherence 
because they are more conscientious of the importance of adherence for viral 
suppression. Finally, it is possible that women may underreport use because they have 
been given misinformation that ART is risky during early pregnancy. 
Interestingly, the findings from the sensitivity analysis conducted using detectable 
viral load as a secondary measurement of poor adherence, support the third and fourth 
hypotheses outlined above. When using detectable viral load rather than self-reported 
adherence, trying to conceive is no longer significantly associated with poor adherence. 
When examining this sensitivity analysis, the independent risk factors appear more 
similar to those of the WIHS cohort of women, including lower educational level and 
lower CD4 count. There is very little research on the impact of pregnancy intentions on 
ART adherence in South Africa, and most identified barriers to poor adherence among 
women of reproductive age are structural in nature, including financial constraints, stock-
outs of pills, distance from clinic, migration, service accessibility, etc. [22, 34].   
4.2 Limitations 
The main limitation of this study is that because of the disparate nature of the 
study questions and study design, the risk factors for poor adherence in the two cohorts 
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could not be directly compared. Additionally, while often cited as important barriers, it 
was not possible to examine perceived or real structural barriers to adherence, because 
these data were not available in either cohort. Other important risk factors for poor 
adherence that could not be studied that have been previously identified include side 
effects of ART, pill burden, maternal knowledge of HIV transmission and PMTCT, 
stigma associated with living with HIV, etc. Another important limitation of this study is 
that it utilizes a cross-sectional design, examining risk factors and poor adherence at a 
single time point, and therefore causal inference is not appropriate. Adherence is difficult 
to measure and while self-report can be low-cost and easily collected, it assumes that 
individuals are able to recall their adherence accurately and are also being honest in their 
reporting. We tried to parse out the accuracy of self-report using detectable viral load as a 
proxy for poor adherence, but viral load can vary between individuals for reasons others 
than ART adherence [26]. Finally, although an assessment for selection bias was 
performed and no appreciable differences were seen between source populations and 
study populations, there is a potential for selection bias because of the study design and 
the strict inclusion criteria (Appendix). 
4.3 Conclusion 
Adherence to ART is of particular importance for women of reproductive age 
living with HIV. Risk factors for poor adherence may differ in different contexts. Further 
research is needed to isolate the effect of these factors to evaluate causal relationships; in 
particular, the effect of pregnancy intention on ART adherence should be considered.  
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Table 1. Characteristicsa of HIV-infected women on antiretroviral therapy in the United States, stratified by whether or not 






























Less than high school 
Some high school 















































Median parity (IQR) 2 (1, 3) 2 (1, 3) 2 (1, 4) 0.004 
None 
One 

























































For continuous variables, p-values estimated using Wilcoxon-rank sums test for equality of medians. 
For categorical variables, p-values estimated using Pearson’s chi-square test for independence.   
IQR=Interquartile range 
HAART=Highly active antiretroviral therapy 
a Measured at index-1 visit, between 2002 and 2014. 
b Women asked if they had experienced a pregnancy outcome in the last six months. 
c Categorized as being in a relationship if either married or living with partner.   
d Categorized as not trying if stated not trying or pregnant at index-1 visit 




























Table 2. Characteristicsa of HIV-infected women on antiretroviral therapy in South Africa, stratified by whether or not experienced a 
pregnancy during duration of follow-upb (n=730) 
For continuous variables, p-values estimated using Wilcoxon-rank sums test for equality of medians. 
































Primary or less 
Some secondary 

































Median parity (IQR) 1 (1, 2) 1 (1, 2) 1(1, 2) 0.530 
None 
One to two 

































Time on HAART 
Less than one year 
Between one and four years 
























HAART=Highly active antiretroviral therapy 
a Measured at baseline study visit, 2009-2010 
b For 12 months or for duration of pregnancy.  
c Data missing on monthly household income (n=18) 





























Table 3.  Crude and adjusted prevalence ratios for risk factors of self-reported poor adherence a among a cohort of women in the 
United States (n=902) 
 
 
 Crude Prevalence Ratio 95% CI Adjusted Prevalence Ratio 95% CI 
Pregnancy outcome 
     No pregnancy outcome reported 













Patient characteristics, general 
Age 
      18-24 
      25-33 


















      Below poverty line 














      Less than HS 
      HS 


















     Non-Black 














Relationship status  
     Single 













Currently trying to conceive 
    Not currently trying 














    None 














    Two or more 1.28 (0.98, 1.66) 1.12  (0.76, 1.65) 
Medication-related and patient-provider relations 
CD4 count 
    0-200 
    201-350 
    351-500 






















    No insurance 














   No depressive symptoms 













Illicit drug use 
  No drug use 















a Self-reported poor adherence defined as being adherent less than 95% of the time in the last six months.  














Table 4.  Crude and adjusted prevalence ratios for risk factors of self-reported poor adherence a among South African women (n=730) 
 
 Crude Prevalence Ratio 95% CI Adjusted Prevalence Ratio 95% CI 
Pregnancy during follow-up 
     Not pregnant during follow-up 













Patient characteristics, general 
Age 
      18-24 
      25-33 


















      Below poverty line 














      Primary or less 
      Some secondary 


















Current partner HIV status 
Single or regular partner HIV positive/unknown 

















Currently trying to conceive 
    Not currently trying 














    None 
    One to two 





























    201-350 
    351-500 













Time on HAART 
   Less than one year 
   Between one and four years 


















Provider talk  
  Cannot talk to provider 














ART= Antiretroviral therapy 
HAART= Highly active antiretroviral therapy 
a Self-reported poor adherence defined as being adherent less than 95% of the time in the last fourteen days  













Table 5.  Sensitivity Analysis: Crude and adjusted prevalence ratios for risk factors of poor adherence defined as having a viral load 
below the detectable limit a among South African women (n=730) 
 
Risk factors Crude Prevalence 
Ratio 
95% CI Adjusted Prevalence 
Ratio 
95% CI 
Pregnancy during follow-up 
     Not pregnant during follow-up 













Patient characteristics, general 
Age 
      18-24 
      25-33 


















      Below poverty line 














      Primary or less 
      Some secondary 


















Current partner HIV status 
     Single or regular partner HIV positive/unknown 













Currently trying to conceive 
    Not currently trying 














    None 
    One to two 



















    0-200 
    201-350 


















    >500 0.54 (0.33, 0.87) 0.46 (0.26, 0.80) 
Time on HAART 
   Less than one year 
   Between one and four years 


















Provider talk c 
  Cannot talk to provider 













ART= Antiretroviral therapy 
HAART= Highly active antiretroviral therapy 
a Poor adherence defined as detectable viral load (greater than or equal to 50 copies per milliliter) 
b Data missing on monthly household income (n=18) 






















Table 6.  Sensitivity Analysis: Crude and adjusted prevalence ratios for risk factors of self-reported poor adherence a among South 
African women (n=730) 
 
Risk factors Crude Prevalence 
Ratio 
95% CI Adjusted Prevalence 
Ratio 
95% CI 
Pregnancy during follow-up 
     Not pregnant during follow-up 













Patient characteristics, general 
Age 
      18-24 
      25-33 


















      Below poverty line 














      Primary or less 
      Some secondary 


















Current partner HIV status 
     Single or regular partner HIV positive/unknown 













Currently trying to conceive 
    Not currently trying 














    None 
    One to two 



















    0-200 
    201-350 


















    >500 0.94 (0.47, 1.89) 1.06 (0.43, 2.64) 
Time on HAART 
   Less than one year 
   Between one and four years 


















Provider talk c 
  Cannot talk to provider 













ART= Antiretroviral therapy 
HAART= Highly active antiretroviral therapy 
a Self-reported poor adherence defined as being adherent less than 85% of the time in the last fourteen days 
b Data missing on monthly household income (n=18) 


























USA South Africa 
STUDY DESIGN     
   Number of sites 6 study sites 4 Primary health centers  
Time period 2002-2014 2009-2011 
Frequency of study visits Every 6 months 1-3 month intervals  
Follow-up time 12 months 12 months or duration of pregnancy 
Pregnancy status Pregnancy outcome observed at index visit Pregnancy during follow up 
COHORT CHARACTERISTICS     
Age ≤52 18-35 
Total number of participants 902 850 
Number retained (retention rate) 902 (100%) 730 (85.9%) 
Number of women who experienced 
pregnancy/pregnancy outcome (% of 
total) 287 (31.8%) 161 (22.1%) 
Living with HIV YES YES 
On antiretroviral therapy YES YES 
Male partner? YES YES 




Figure 5. Definition of poor adherence by cohort and level of analysis: self-reported adherence and viral load as a proxy for 
adherence 
 
COHORT ANALYSIS COLLECTED Poor adherence defined as 
USA Primary Self-report: How often did you take 
ARVs over the past 6 months? 
100% of the time 
95-99% of the time 
75-94% of the time 
<75% of the time 
Taking ARVs <95% of the time. 
South Africa Primary Self-report: How many days in the last 
two weeks have you missed taking 
your ARV pills for any reason? 
Missed pills on one or more days (<95%). 
South Africa Sensitivity Self-report: How many days in the last 
two weeks have you missing taking 
your ARV pills for any reason? 
Missed pills on three or more days (<85%). 































































Figure 7. Forest plot of patient demographics as predictors of poor adherence among HIV-infected women on antiretroviral 
therapy in the United States, overall (n=902) 
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Figure 8. Forest plot of reproductive-health characteristics as predictors of poor adherence among HIV-infected women on 
antiretroviral therapy in the United States, overall (n=902) 
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Figure 9. Forest plot of medication-related characteristics as predictors of poor adherence among HIV-infected women on 
antiretroviral therapy in the United States, overall (n=902) 
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Figure 10. Forest plot of patient demographics as predictors of poor adherence among HIV-infected women on antiretroviral 





Figure 11. Forest plot of reproductive-health characteristics as predictors of poor adherence among HIV-infected women on 






Figure 12. Forest plot of medication-related characteristics as predictors of poor adherence among HIV-infected women on 
antiretroviral therapy in the United States stratified by whether or not they experienced a pregnancy outcome by the index 





Figure 13. Forest plot of patient demographics as predictors of poor adherence among HIV-infected women on antiretroviral 
therapy in South Africa, overall (n=730) 
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Figure 14. Forest plot of reproductive-health characteristics as predictors of poor adherence among HIV-infected women on 
antiretroviral therapy in South Africa, overall (n=730) 
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Figure 15. Forest plot of medication-related characteristics as predictors of poor adherence among HIV-infected women on 
antiretroviral therapy in South Africa, overall (n=730) 
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Figure 16. Forest plot of patient demographics as predictors of poor adherence among HIV-infected women on antiretroviral 





Figure 17. Forest plot of reproductive-health characteristics as predictors of poor adherence among HIV-infected women on 
antiretroviral therapy in South Africa stratified by whether or not they experienced a pregnancy during follow-up (n=730)  ( 






Figure 18. Forest plot of medication-related characteristics as predictors of poor adherence among HIV-infected women on 
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Table 1a. Characteristics a of 1305 HIV-infected women on antiretroviral therapy in the United States, stratified by whether or not 






















Yearly income above poverty line 









Less than high school 
Some high school 

























Relationship status c, f 








Currently trying to conceive d 








Median parity (IQR) i 2 (1, 3) 2 (1, 3) 2 (1, 4) 0.006 
None 
One 



















































Illicit drug use 









For continuous variables, p-values estimated using Wilcoxon-rank sums test for equality of medians. 
For categorical variables, p-values estimated using Pearson’s chi-square test for independence.   
IQR=Interquartile range 
HAART=Highly active antiretroviral therapy 
a Measured at index-1 visit, between 2002 and 2014. 
b Women asked if they had experienced a pregnancy outcome in the last six months. 
c Categorized as being in a relationship if either married or living with partner.   
d Categorized as not trying if stated not trying or pregnant at index-1 visit 

























Table 2a. Characteristicsa of 850 HIV-infected women on antiretroviral therapy in South Africa, stratified by whether or not 
experienced a pregnancy during duration of follow-upb 
For continuous variables, p-values estimated using Wilcoxon-rank sums test for equality of medians. 























Monthly income above poverty line 










Primary or less 
Some secondary 

















Relationship status d 








Currently trying to conceive 








Median parity (IQR) 1 (1, 2) 1 (1, 2) 1 (1, 2) 0.937 
None 
One to two 

































Time on HAART 
Less than one year 
Between one and four years 
























HAART=Highly active antiretroviral therapy 
a Measured at baseline study visit, 2009-2010 
b For 12 months or for duration of pregnancy.  
c Data missing on monthly household income (n=20) 
d Categorized as being in a relationship by self-reported relationship status. 
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